Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.46)
# 451
Out of 5,182 analysts
130
Total ratings
50.88%
Success rate
22.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAR Pharming Group | Initiates: Buy | $37 | $17.57 | +110.59% | 1 | Apr 10, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $14 → $17 | $6.46 | +163.16% | 12 | Apr 6, 2026 | |
| NGNE Neurogene | Maintains: Buy | $200 → $180 | $27.74 | +548.88% | 2 | Apr 6, 2026 | |
| GUTS Fractyl Health | Maintains: Buy | $8 | $0.58 | +1,290.10% | 3 | Mar 26, 2026 | |
| OCGN Ocugen | Initiates: Buy | $12 | $1.85 | +548.65% | 1 | Mar 17, 2026 | |
| WVE Wave Life Sciences | Maintains: Buy | $43 → $52 | $7.58 | +586.02% | 4 | Mar 10, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $66 → $21 | $8.90 | +135.96% | 7 | Mar 5, 2026 | |
| PASG Passage Bio | Maintains: Buy | $67 → $23 | $6.25 | +268.00% | 8 | Mar 4, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $54 → $48 | $15.21 | +215.58% | 7 | Mar 3, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $140 | $87.72 | +59.60% | 11 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $104 | $54.88 | +89.50% | 10 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $74 | $31.19 | +137.26% | 1 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $79 | $25.06 | +215.24% | 10 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $411 → $441 | $439.18 | +0.41% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $429 | $310.94 | +37.97% | 10 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $0.74 | +574.40% | 7 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $204 | $129.33 | +57.74% | 8 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $3.86 | +159.07% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $21.42 | +600.28% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $135.87 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $8.94 | +2,584.56% | 4 | Jul 23, 2019 |
Pharming Group
Apr 10, 2026
Initiates: Buy
Price Target: $37
Current: $17.57
Upside: +110.59%
Taysha Gene Therapies
Apr 6, 2026
Maintains: Buy
Price Target: $14 → $17
Current: $6.46
Upside: +163.16%
Neurogene
Apr 6, 2026
Maintains: Buy
Price Target: $200 → $180
Current: $27.74
Upside: +548.88%
Fractyl Health
Mar 26, 2026
Maintains: Buy
Price Target: $8
Current: $0.58
Upside: +1,290.10%
Ocugen
Mar 17, 2026
Initiates: Buy
Price Target: $12
Current: $1.85
Upside: +548.65%
Wave Life Sciences
Mar 10, 2026
Maintains: Buy
Price Target: $43 → $52
Current: $7.58
Upside: +586.02%
Arcturus Therapeutics Holdings
Mar 5, 2026
Maintains: Buy
Price Target: $66 → $21
Current: $8.90
Upside: +135.96%
Passage Bio
Mar 4, 2026
Maintains: Buy
Price Target: $67 → $23
Current: $6.25
Upside: +268.00%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $54 → $48
Current: $15.21
Upside: +215.58%
Rhythm Pharmaceuticals
Mar 2, 2026
Maintains: Buy
Price Target: $141 → $140
Current: $87.72
Upside: +59.60%
Feb 26, 2026
Maintains: Buy
Price Target: $98 → $104
Current: $54.88
Upside: +89.50%
Feb 20, 2026
Initiates: Buy
Price Target: $74
Current: $31.19
Upside: +137.26%
Feb 18, 2026
Maintains: Buy
Price Target: $128 → $79
Current: $25.06
Upside: +215.24%
Feb 17, 2026
Maintains: Hold
Price Target: $411 → $441
Current: $439.18
Upside: +0.41%
Feb 17, 2026
Maintains: Buy
Price Target: $415 → $429
Current: $310.94
Upside: +37.97%
Dec 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.74
Upside: +574.40%
Dec 16, 2025
Maintains: Buy
Price Target: $148 → $204
Current: $129.33
Upside: +57.74%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $3.86
Upside: +159.07%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $21.42
Upside: +600.28%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $135.87
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $8.94
Upside: +2,584.56%